New hope for rare, aggressive head and neck cancer
NCT ID NCT07162480
Summary
This study is testing a new drug called puxitatug samrotecan (AZD8205) in patients with an aggressive form of a rare salivary gland cancer called adenoid cystic carcinoma that has returned or spread. The main goals are to see if the drug shrinks tumors and is safe for patients. The trial will enroll about 28 adults whose cancer has specific genetic or biological features and has progressed despite prior treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.